Press release -
Proteomics on NGS: The launch of Olink Explore 1536 will be a game changer
Uppsala, Sweden, June 3, 2020:
Olink Proteomics today announces the launch of Olink® Explore 1536, combining the company's unique proximity extension assay (PEA) high-multiplex immunoassay technology with next-generation sequencing (NGS) readout on the Illumina® NovaSeq platform.
Olink Explore 1536 has several groundbreaking features that overcome significant limitations in other proteomic technologies, including remarkably increased performance in terms of multiplexing and throughput. We have achieved these dramatic improvements while maintaining the same robust, transparent and thorough validation of each assay as previously, generating reproducible and precise data that can be trusted.
"I am extremely proud of the Olink team that has been able to take this technology leap and apply NGS as our readout platform. A lot of efforts have been made to respond to a rapidly growing unmet need; drastically increase multiplexing, throughput, drive cost down and leveraging a large installed base to increase access. It is also important that we will rapidly expand our strictly validated protein biomarker library, now in excess of 1500, next year beyond 3000 and reaching 4500 in 2022. This new platform marks a pivotal moment in the field, taking discovery in proteomics to unparalleled levels and supporting our vision to enable the understanding of real-time human biology in a liquid biopsy", says Jon Heimer, CEO, Olink Proteomics
"I think that Olink will be an important addition to the tools we have for biomarker discovery in plasma, CSF, and other biofluids due to the speed and very small sample amounts required for analysis", says Professor Steven Carr, Senior Director of Proteomics at the Broad Institute.
Product details
Olink Explore 1536 enables rapid measurement of more than 1460 human proteins in only <3 µL of plasma or serum. These carefully selected proteins provide broad coverage of the low abundant plasma proteome, and this is just the first major step in the development of Olink's planned NGS-based library. The power of the NGS platform combined with a semi-automated assay workflow enables unprecedented levels of throughput, with over 1.35 million protein measurements/ week/ system. Each thoroughly validated assay maintains the exceptional standards of specificity, sensitivity, precision and dynamic range that Olink users have come to expect from its well-established range of 96-plex biomarker panels with qPCR readout. Those panels have so far resulted in over 166 million protein data points measured and almost 400 peer-reviewed publications. Olink Explore 1536 now takes this to the next level. The new platform is currently available via fee-for-service at our Analysis Service labs in Uppsala, Sweden and Boston MA, USA, for human plasma or serum samples.
Full details are available on the Olink Explore website at www.olinkexplore.com
Questions?
If you have any questions regarding this product, please contact Jon Heimer:
Email: jon.heimer@olink.com
Cell: +46 761 17 18 20
Related links
Topics
- Medical research
Categories
- protein biomarkers
- next generation sequencing
- precision medicine
- proteomics
- high throughput
- biomarkers
About Olink Proteomics
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume, we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.
For more information, please visit www.olink.com. Olink® is a registered trademark of Olink Proteomics AB.
